AHOF has won their first music show trophy for their new title track “Pinocchio”! On the November 11 episode of “The Show,” the candidates for first place were AHOF’s “Pinocchio,” ARrC’s “SKIID,” and ...

AHOF is finally back with their second album! On November 4 at 6 p.m. KST, AHOF released their second mini album “The Passage” along with the music video for its title track “Pinocchio.” “Pinocchio” ...

More than a third of patients with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) treated with the CAR T-cell therapy obecabtagene autoleucel (obe-cel) remained in remission at a ...

CEL-SCI Corporation (NYSE:CVM) shares tumbled 38.19% in after-hours trading to $8.06 on Tuesday following the cancer immunotherapy company’s announcement of a $10 million public offering priced below ...

VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a clinical stage cancer immunotherapy company, today announced that it intends to offer to sell ...

Obecabtagene autoleucel showed effective outcomes in both younger and older adults with relapsed/refractory B-cell acute lymphoblastic leukemia, with similar remission rates and chimeric antigen ...

He will also serve as an executive producer on the indie project, which a steampunk-inspired take on the classic story. By Aaron Couch Film Editor The film is a steampunk-inspired take on the classic ...

GameSpot may get a commission from retail offers. The spectacular new Fortnite Superman. As you can see, we've got a cel-shaded look with a rather unique version of the Superman logo with the S on a ...

Ciara Freeman, MD, PhD, discusses the challenges of incorporating anito-cel into the treatment protocol for patients with multiple myeloma. Ciara Freeman, MD, PhD, a medical oncologist at Moffitt ...

Cema-cel demonstrated durable responses in relapsed/refractory large B-cell lymphoma, with high overall and complete response rates comparable to autologous CAR-T therapies. The safety profile of cema ...

The FIRCE-1 trial for firi-cel in LBCL patients was discontinued due to insufficient therapeutic advantage and safety concerns. Firi-cel showed a 77% overall response rate, but only 18% of complete ...